UOS Tumori Polmonari, IRCCS AOU San Martino IST - Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy.
Future Oncol. 2014 Jan;10(1):79-90. doi: 10.2217/fon.13.145.
After several decades of modest results with nonspecific immune stimulants, immunotherapy has become an exciting approach in the treatment of cancer. Although non-small-cell lung cancer has not been considered an immunogenic disease for very long, a better understanding of tumor immunology and the identification of new targets have led to the development of many clinical trials of immune-based therapies for this neoplasm. Promising results from many clinical trials suggest that immunotherapy could be an effective strategy in the management of advanced non-small-cell lung cancer. Further studies are required to help clinicians in the selection of patients who are more likely to benefit from immunotherapy strategies by the identification of biomarkers and to understand when the combination of immunotherapy with other agents should be recommended.
经过几十年对非特异性免疫刺激剂的适度研究，免疫疗法已成为癌症治疗中令人兴奋的方法。虽然很长一段时间以来，非小细胞肺癌都不被认为是一种免疫原性疾病，但对肿瘤免疫学的更好理解和新靶标的确定，导致了针对这种肿瘤的许多免疫疗法临床试验的发展。许多临床试验的有希望结果表明，免疫疗法可能是治疗晚期非小细胞肺癌的有效策略。需要进一步的研究来帮助临床医生通过识别生物标志物选择更有可能从免疫疗法策略中获益的患者，并了解何时应推荐将免疫疗法与其他药物联合使用。
